Back to announcement
20240719_BMHS_Laporan Informasi dan Fakta Material_31685890_lamp1.pdf
Other Text extracted BMHSSource file signed link, expires in 15 minutes
Extracted text 6
Page 1 OCR 0.922
( bmhs Ns since 1973 No.: 055-K/CORSEC/BMHS/VII/2024 19 Juli 2024 / July 19", 2024 Kepada Yth./To: Otoritas Jasa Keuangan (Financial Services Authority or “OJK”) Gedung Sumitro Djojohadikusumo, Lantai 3 Jl. Lapangan Banteng Timur 2-4 Jakarta - 10710 U.p: Kepala Eksekutif Pengawas Pasar Modal/ Chief Executive of Capital Market Supervision Dengan hormat, Dear Sir/Madam, Perihal/ : Laporan Informasi atau Fakta Material/ Subject Report on Material Information or Facts Guna memenuhi Peraturan OJK No. 31/POJK.04/2015 tanggal 16 Desember 2015 tentang Keterbukaan Atas Informasi atau Fakta Material oleh Emiten Atau Perusahaan Publik (“POJK 31”) dan Keputusan Direksi Bursa Efek Indonesia No. KEP-00066/BEI/09-2022 tanggal 30 September 2022 perihal Perubahan Peraturan No. I-E tentang Kewajiban Penyampaian Informasi (“Peraturan BEI No. I-E”), dengan ini, kami, PT Bundamendik Tbk. (“Perseroan”) bermaksud untuk menyampaikan Laporan Informasi atau Fakta Material sebagai berikut: In order to comply with OJK Regulation No. 31/POJK.04/2015 dated 16 December 2015 regarding Disclosure of Information or Material Facts by the Issuers or Public Companies (“POJK 31”) and Directors Decree of Indonesia Stock Exchange No. KEP-00066/BEI1/09-2022 dated 30 September 2022 regarding the Amendment to Regulation No. I-E on the Obligation to Submit Information (IDX Regulation No. I-E”), we, PT Bundamendik Tbk. (the “Company”) hereby intend to submit the Report on Material Information or Facts as follows: Nama Emiten/Issuers PT Bundamedik Tbk. Bidang Usaha/Scope of Business Aktivitas rumah sakit swasta. Activities of private hospitals. Telepon/ Phone Faksimili/ Fax Alamat Surat Elektronik (e-mail) 1. Tanggal Kejadian/ Date of Event 2. Jenis Informasi atau Fakta Material / Type of Material Information or Facts From Embryo Throughout 021- 5098 0799 021- 3190 5915 corsec@bmhs.co.id 19 Juli 2024 / July 19, 2024 Penyelesaian rencana transaksi berdasarkan Perjanjian Pengambilan Bagian dan Pembelian Saham yang telah ditandatangani pada tanggal 1 April 2024 (“Perjanjian 1 April 2024”) oleh PT Morula Indonesia (“MP”) (anak Perusahaan terkendali PT Bundamedik Tbk Jl. Teuku Cik Ditiro No. 28, Menteng, Jakarta 10350, Indonesia Head Office: HDI Hive Menteng, 6-7" Floor, Jl. Probolinggo No. 18, Menteng, Jakarta 10350, Indonesia 4462 2150980799 & www.bmhs.co.id Je
Page 2 OCR 0.931
@ bmhs
since 1973
Perseroan), Perseroan, PT Bunda Ipiti Investama
(“BIPI”), Ivan Rizal Sini, Mesha Rizal Sini dan Jinxin
Fertility Group (BVI) Company Limited (Jinxin BVI”)
(MI, Perseroan, BIPI, Ivan Rizal Sini, Mesha Rizal Sini
dan Jinxin BVI secara bersama-sama, “Para Pihak”).
The completion of the proposed transaction under the
Shares Subscription and Purchase Agreement, which
was executed on 1 April 2024 (“Agreement dated 1
April 2024”) by PT Morula Indonesia ("MI") (a
controlled subsidiary of the Company), the Company,
PT Bunda Ipiti Investama (“BIPI”), Ivan Rizal Sini,
Mesha Rizal Sini and Jinxin Fertility Group (BVI)
Company Limited (Jinxin BVI”) (MI, Perseroan, BIPI,
Ivan Rizal Sini, Mesha Rizal Sini and Jinxin BVI,
collectively, “Parties”).
3. Uraian Informasi atau Fakta : Dengan merujuk pada POJK 31 dan Peraturan BEI No.
Material/ Description of I-E, Perseroan dengan ini memberitahukan bahwa:
Material Information or Facts
a. Para Pihak telah menandatangani Perjanjian 1
April 2024 sehubungan dengan rencana (i)
penerbitan 48.333 (empat puluh delapan ribu
tiga ratus tiga puluh tiga) saham baru oleh MI
yang mewakili 25y6 (dua puluh lima persen) dari
total modal ditempatkan dan modal disetor MI
yang seluruhnya akan diambil bagian oleh Jinxin
BVI (“Pengambilan Bagian Saham”), dan (b)
penjualan 596 (lima persen) saham milik BIPI
(salah satu pemegang saham MI) dalam MI
kepada Jinxin BVI (“Pembelian Saham”)
(Rencana Pengambilan Bagian Saham dan
Pembelian Saham sebagaimana diuraikan di atas
selanjutnya disebut “Transaksi”).
b. Merujuk pada POJK 31 dan Peraturan BEI No.I-E,
pada tanggal 1 April 2024, Perseroan telah
menyampaikan Laporan Keterbukaan Informasi
kepada OJK dan masyarakat — atas
penandatanganan Perjanjian 1 April 2024
melalui Surat Perseroan No.013-
K/CORSEC/BMHS/IV/2024.
c. Pada tanggal 16 Juli 2024, Para Pihak telah
menandatangani — Amandemen Perjanjian
Pengambilan Bagian dan Pembelian Saham
(“Amandemen 16 Juli 2024”) untuk mengatur,
antara lain, pengalihan hak dan kewajiban untuk
melaksanakan Transaksi yaitu dari Jinxin BVI
kepada Jinxin Life Asia Healthcare Investment
Group Pte. Ltd., suatu perusahaan yang didirikan
&
PT Bundamedik Tbk
JI. Teuku Cik Ditiro No. 28, Menteng, Jakarta 10350, Indonesia
Head Office: HDI Hive Menteng, 6"-7" Floor, Jl. Probolinggo No. 18, Menteng, Jakarta 10350, Indonesia
4622150980799 & www.bmhs.co.id
From Embryo Throughout Life
Page 3 OCR 0.928
( bmhbs NN, since 1973 menurut hukum Singapura (Jinxin Singapore”). d. Pada tanggal 19 Juli 2024 (“Tanggal Penyelesaian”) Para Pihak telah melaksanakan Transaksi. Dengan demikian, terhitung sejak Tanggal Penyelesaian, Jinxin Singapore memiliki total 30Y6 (tiga puluh persen) saham dalam MI dan kepemilikan saham Perseroan dalam MI berkurang dari sebelumnya 6396 (enam puluh tiga persen) menjadi 47.256 (empat puluh tujuh koma dua lima persen) dari seluruh modal ditempatkan dan modal disetor MI namun tidak terjadi perubahan pengendalian dalam MI dimana Perseroan tetap menjadi pemegang saham mayoritas MI dan laporan keuangan MI tetap dikonsolidasikan ke dalam laporan keuangan Perseroan. Nilai Transaksi adalah sebesar (i) Rp351.690.000.000 (tiga ratus lima puluh satu milyar enam ratus sembilan puluh juta Rupiah) yang diterima oleh MI untuk Pengambilan Bagian Saham, dan (ii) Rp70.340.000.000 (tujuh puluh milyar tiga ratus empat puluh juta Rupiah) yang diterima oleh BIPI untuk Pembelian Saham. e. Berdasarkan Perjanjian 1 April 2024 sebagaimana diubah dengan Amandemen 16 Juli 2024 (“Dokumen Transaksi"), Perseroan telah sepakat untuk menjamin pelaksanaan kewajiban MI (Jaminan Perseroan”), selaku anak perusahaan terkendali Perseroan, berdasarkan syarat dan ketentuan sebagaimana diatur dalam Dokumen Transaksi. Jaminan Perseroan belum berlaku efektif pada Tanggal Penyelesaian dan baru akan berlaku efektif setelah dipenuhinya seluruh persyaratan sebagaimana diatur dalam Dokumen Transaksi. Jaminan Perseroan merupakan transaksi afiliasi berdasarkan Peraturan OJK No. 42/POJK.04/2020 tanggal 1 Juli 2020 tentang Transaksi Afiliasi dan Transaksi Benturan Kepentingan Transaksi (“POJK 42”). Jaminan Perseroan juga merupakan transaksi material sebagaimana dimaksud dalam Peraturan OJK No. 17/POJK.04/2020 tentang Transaksi Material dan Perubahan Kegiatan Usaha (“POJK 17”) dimana nilainya melebihi 206 (dua puluh persen) namun kurang dari 5096 (lima puluh persen) dari nilai ekuitas Perseroan PT Bundamedik Tbk J- Jl. Teuku Cik Ditiro No. 28, Menteng, Jakarta 10350, Indonesia Head Office: HDI Hive Menteng, 6”-7” Floor, Jl. Probolinggo No. 18, Menteng, Jakarta 10350, Indonesia (462 2150980799 & www.bmhs.co.id roughout Life
Page 4 OCR 0.905
since 1973
@ bmhs
berdasarkan Laporan Keuangan Perseroan.
Dengan demikian, Perseroan juga akan
melakukan Keterbukaan Informasi dalam waktu
paling lambat 2 (dua) hari kerja setelah tanggal
efektifnya pemberian Jaminan Perseroan sesuai
dengan syarat dan ketentuan sebagaimana
diatur dalam POJK 42 dan POJK 17.
With reference to POJK 31 and IDX Regulation No. I-E,
the Company hereby notifies that:
a. The Parties executed the Agreement Dated 1 April
2024, in relation to the proposed (i) issuance of
48,333 (forty-eight thousand three hundred thirty-
three) new shares by MI representing 2546 (twenty-
Jive percent) of the total issued and paid up capital
Of MI which would be fully subscribed by Jinxin BVI
(“Shares Subscription"): and (ii) the sale of 54
(five percent) of the shares owned by BIPI (one of
the shareholders of MI) in MI to Jinxin BVI ("Shares
Purchase”) (Shares Subscription and Shares
Purchase as described above hereinafter shall be
referred to as the "Transaction”).
b. Referring to POJK 31 and IDX Regulation No. I-E,
on April 15, 2024, the Company has submitted the
Information Disclosure Report to OJK and the
public regarding the execution of the Agreement
Dated 1 April 2024 based on the Company's Letter
No. 013-K/CORSEC/BMHS/IV/2024.
c. On 16 July 2024, the Parties executed the
Amendment Agreement to the Shares Subscription
and Purchase Agreement (“Amendment Dated 16
July 2024”) to set out, among others, assignment of
rights and obligations to implement the
Transaction from Jinxin BVI to Jinxin Life Asia
Healthcare Investment Group Pte. Ltd, a company
incorporated under the laws of Singapore ("Jinxin
Singapore”).
d. OnJuly 19", 2024 (“Completion Date”), the Parties
have implemented the Transaction. Therefore, as of
the Completion Date, Jinxin Singapore owns a total
of 3016 (thirty percent) of MI's shares, and the
Company' shareholding in MI decreases from 6316
(sixty-three percent) to 47.2516 (forty-seven point
two five percent) of the total issued and paid-up
capital of MI, but there is no change of control in MI,
whereby the Company remains the majority
shareholders of MI and MIS financial statements
J3.
PT Bundamedik Tbk
Jl. Teuku Cik Ditiro No. 28, Menteng, Jakarta 10350, Indonesia
Head Office: HDI Hive Menteng, 6"-7" Floor, Jl. Probolinggo No. 18, Menteng, Jakarta 10350, Indonesia
4462 2150980799 @& www.bmhs.co.id
From Embryo
Page 5 OCR 0.922
(@ bmhs
since 1973
continue to be consolidated into the Company's
Jinancial statements.
The Transaction Value is (i) IDR 351,690,000,000
(three hundred and fifty-one billion six hundredand
ninety million Rupiah) for the Shares Subscription,
which is received by MI, and (ii) IDR 70,340,000,000
(seventy billion three hundred and forty million
Rupiah) which is received by BIPI for the Shares
Purchase.
e. Based on the Agreement Dated 1 April 2024 as
amended based on the Amendment Dated 16 July
2024 (“Transaction Documents”), the Company
has agreed to guarantee the implementation of the
obligations of MI (“Guarantee by the Company”),
as a controlled subsidiary of the Company, based on
the terms and conditions as set forth in the
Transaction Documents. The Guarantee by the
Company has yet to be effective on the Completion
Date and will only be effective upon the fulfillment
ofall reguirements as stipulated in the Transaction
Documents.
The Guarantee by the Company shall constitute an
affiliated party transaction based on OJK
Regulation No. 42/POJK.04/2020 dated July 1, 2020
concerning Affiliated Transactions and Conflict of
Interest Transactions ("POJK 42").
The Guarantee by the Company shall also
constitute ad material transaction as regulated
under OJK Regulation No. 17/POJK.04/2020
regarding Material Transactions and Changes of
Business Activities (“POJK 17”) where the value
exceeds 20Y6 (twenty percent) but less than 5016
(fifty percent) of the Company's eguity value
based on the Company's Financial Statements.
Therefore, the Company will conduct Information
Disclosure no later than 2 (two) business days after
the effective date of the Guarantee by the Company
in accordance with the terms and conditions as
stipulated in POJK 42 and POJK 17.
4. Dampak kejadian, informasi : Transaksi tidak memiliki dampak negatif
atau fakta material tersebut terhadap kegiatan operasional, hukum,
terhadap Emiten atau kondisi keuangan atau kelangsungan usaha
Perusahaan Publik / Impact of Perseroan.
such event information or
material facts towards Issuer or The Transaction does not have a negative
Public Company impact on the operational activities, legal,
aka
PT Bundamedik Tbk
Jl. Teuku Cik Ditiro No. 28, Menteng, Jakarta 10350, Indonesia
Head Office: HDI Hive Menteng, 6"-7" Floor, Jl. Probolinggo No. 18, Menteng, Jakarta 10350, Indonesia
4622150980799 & www.bmhs.co.id
Throughout Life
Page 6 OCR 0.932
(& bmhs Ns since 1973 financial conditions or going-concern of the Company. 5. Keterangan lain-lain/ Others : a. Laporan ini dilakukan oleh Perseroan untuk Information menjalankan tata kelola perusahaan yang baik dan untuk memenuhi ketentuan POJK 31. b. Jinxin Singapore bukan merupakan pihak afiliasi Perseroan. a. This report is carried out by the Company to Implement good corporate governance and to Julfill the provisions of POJK 31. b. Jinxin Singapore is notan affiliated party of the Company. Laporan ini kami sampaikan dalam Bahasa Indonesia dan Bahasa Inggris. Apabila terdapat perbedaan antara versi Bahasa Indonesia dan versi Bahasa Inggris, maka yang berlaku adalah versi Bahasa Indonesia dan versi Bahasa Inggris akan diartikan mengikuti Bahasa Indonesia. This report is made in Indonesian and English language versions. In the event of any discrepancies between the Indonesian and English language versions, the Indonesian language version will prevail and the English language version will be construed in accordance with the Indonesian language version. Demikian laporan ini kami sampaikan. Thus, we submit this report. Terima kasih atas perhatian dan kerjasamanya. Thank you for your attention. Hormat kami/ Sincerely yours, PT Bundamedik Tbk 973 PT Bundamedik Tbk sephine Tobing Corporate Secretary Tembusan kepada Yth./ Cc: Direksi PT Bursa Efek Indonesia (BEI)/ The Board of Directors of PT Bursa Efek Indonesia (Indonesian Stock Exchange/IDX) PT Bundamedik Tbk Jl. Teuku Cik Ditiro No. 28, Menteng, Jakarta 10350, Indonesia Head Office: HDI Hive Menteng, 6"-7" Floor, Jl. Probolinggo No. 18, Menteng, Jakarta 10350, Indonesia (162 2150980799 & www.bmhs.co.id From Embryo Throughout Life
Names mentioned 12 people and organisations named in the text · linked when the evidence is strong
unresolved
org
Financial Services Authority
p.1
unresolved
org
Bundamendik Tbk.
p.1 ×4
unresolved
org
Indonesia Stock Exchange
p.1
unresolved
org
PT Morula Indonesia
p.1 ×2
unresolved
org
PT Bunda Ipiti Investama
p.2 ×2
unresolved
org
Jinxin Life Asia Healthcare Investment Group Pte. Ltd.
p.2 ×2
unresolved
person
Tembusan kepada Yth./ Cc:
· Direksi PT Bursa Efek Indonesia (BEI)/
p.6
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.